# Chongqing Precision Biotech

Source: https://onco.cc/companies/chongqing-precision-biotech/  
OnCo record `chongqing-precision-biotech` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Chongqing Precision Biotech is a China-based cell therapy company running 2 late-stage cancer trials in multiple myeloma.

## Summary

Chongqing Precision Biotech, based in Chongqing, China, is a cell therapy company. Precision Biotech is a Chinese biopharmaceutical company focused on cell-based drug development, specialising in CAR-T cell immunotherapies including a marketed paediatric/adolescent leukaemia CAR-T product. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials in multiple myeloma. The largest, NCT04271644 (BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease), plans to enrol 80 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Chongqing Precision Biotech Co., Ltd
- Tags: ctgov-sponsor
- HQ: Chongqing
- Type: cell-therapy
- Website: https://www.precision-biotech.com

## Sources

- Official website: https://www.precision-biotech.com
- ClinicalTrials.gov: trials led by Chongqing Precision Biotech: https://clinicaltrials.gov/search?lead=Chongqing%20Precision%20Biotech%20Co.%2C%20Ltd

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)
- trials: [a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease](https://onco.cc/trials/nct04776330/), [A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents](https://onco.cc/trials/nct05334823/), [BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease](https://onco.cc/trials/nct04271644/)

---
JSON: https://onco.cc/api/v1/entities/chongqing-precision-biotech.json